GB202306865D0 - Conjugate and composition for treating cancer - Google Patents
Conjugate and composition for treating cancerInfo
- Publication number
- GB202306865D0 GB202306865D0 GBGB2306865.3A GB202306865A GB202306865D0 GB 202306865 D0 GB202306865 D0 GB 202306865D0 GB 202306865 A GB202306865 A GB 202306865A GB 202306865 D0 GB202306865 D0 GB 202306865D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- conjugate
- composition
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306865.3A GB202306865D0 (en) | 2023-05-10 | 2023-05-10 | Conjugate and composition for treating cancer |
| PCT/ZA2024/050020 WO2024234021A2 (en) | 2023-05-10 | 2024-05-10 | Conjugate and composition for treating cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306865.3A GB202306865D0 (en) | 2023-05-10 | 2023-05-10 | Conjugate and composition for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202306865D0 true GB202306865D0 (en) | 2023-06-21 |
Family
ID=86763458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2306865.3A Ceased GB202306865D0 (en) | 2023-05-10 | 2023-05-10 | Conjugate and composition for treating cancer |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202306865D0 (en) |
| WO (1) | WO2024234021A2 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100021471A1 (en) * | 2008-07-25 | 2010-01-28 | Brookhaven Science Associates, Llc | Carbon nanotube-based drug delivery systems and methods of making same |
| KR20170125811A (en) * | 2014-12-31 | 2017-11-15 | 나노케어 테크놀로지스 인코퍼레이티드 | Jasmonate derivatives and compositions thereof |
-
2023
- 2023-05-10 GB GBGB2306865.3A patent/GB202306865D0/en not_active Ceased
-
2024
- 2024-05-10 WO PCT/ZA2024/050020 patent/WO2024234021A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024234021A3 (en) | 2025-02-27 |
| WO2024234021A2 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299950A (en) | Superantigen conjugate for use in methods and compositions for treating cancer | |
| IL315800A (en) | Compositions and methods for treating cancer | |
| IL309120A (en) | Methods and compositions for treating cancer | |
| EP4445914A4 (en) | Pharmaceutical composition for treating tumors and use | |
| IL304400A (en) | Compositions and methods for preventing tumors and cancer | |
| GB202306865D0 (en) | Conjugate and composition for treating cancer | |
| IL312846A (en) | Methods and compositions for treating cancer | |
| IL309071A (en) | Methods and compositions for treating cancer | |
| IL319403A (en) | Compositions and methods for treating advanced solid tumors | |
| IL299039A (en) | Methods and compositions for treating triple-negative breast cancer | |
| EP4243835A4 (en) | Compositions and methods for treating solid cancer | |
| EP4149508A4 (en) | Compositions and methods for treating cancer | |
| IL314316A (en) | Compounds and their use in treating cancer | |
| IL324490A (en) | Methods and compositions for treating cancer | |
| IL319543A (en) | Compositions and methods for treating cancer | |
| IL316053A (en) | Compositions and methods for treating solid cancer | |
| GB202101728D0 (en) | Compounds and their use treating cancer | |
| GB202402730D0 (en) | Methods and compositions for treating cancer | |
| KR102371980B9 (en) | Composition for preventing or treating pancreatic cancer | |
| HK40102475A (en) | Pharmaceutical combination and pharmaceutical composition for treating cancer | |
| CA3296990A1 (en) | Compositions and methods for treating cancer | |
| CA3291233A1 (en) | Methods and compositions for treating cancer | |
| CA3278391A1 (en) | Compositions and methods for treating cancer | |
| IL324653A (en) | Pharmaceutical composition for treating or preventing cancer | |
| HK40102255A (en) | Method for treating cancer by using antibody-drug conjugate and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |